VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Monday. The brokerage issued a sell rating on the stock.

Other equities analysts also recently issued research reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Down 4.6 %

Shares of VNRX stock opened at $0.60 on Monday. The firm has a market capitalization of $55.60 million, a price-to-earnings ratio of -1.67 and a beta of 1.17. The business’s 50-day moving average price is $0.65 and its 200-day moving average price is $0.66. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Activity

In related news, CEO Cameron John Reynolds bought 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of VolitionRx stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC raised its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.